



ANNUAL REPORT 2021-22

Shaping a Dream



S h a p i n g a D r e a m

Forward-looking statement

In this Annual Report, we have disclosed forward-looking information to enable investors to comprehend our prospects and take investment decisions. This report and our other statements-written and oral- that we periodically make contain forward looking statements that set out anticipated results based on the management plans and the assumptions. We have tried wherever possible to identify such statements by using words such as “anticipate”, “estimate”, “expects”, “projects”, “intends”, “plans”, “believes” and words of similar substance in connection with any decision of future performance. We cannot guarantee that these forward-looking statements will be realised, although we believe we have been prudent in assumptions. The achievements of results are subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialise or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Readers should keep this in mind. We undertake no obligation to publicly update any forward-looking statements, where as a result of new information, future events or otherwise.

Vision



**Become a
composite and
meaning fully integrated
pharmaceutical corporation
competing in differentiated arenas where
greater, more sustainable value can be created**



Corporate Information

Board of Directors

Shri Ram Gopal Agarwal, Chairman & Non-Executive Director

Shri Manish Dhanuka, Managing Director

Shri Mridul Dhanuka, Whole-time Director

Shri Arun Kumar Dhanuka, Non-Executive Director

Smt Tanu Singla, Independent Director

Dr Dharam Vir, Independent Director

Shri Mudit Tandon, Independent Director

Shri Manoj Kumar Goyal, Independent Director

Management Team

Shri Sunil Kumar Gupta, Chief Financial Officer

Dr R J Sarangdhar, Vice President (Unit Head – API & FDF)

Dr Srinivasan S, Head-CTD & IPM

Ms Nikita K, Company Secretary & Compliance Officer

Statutory Auditors

CNGSN & Associates LLP

Chartered Accountants
Flat No.6, Vignesh Apartments,
North Avenue, Srinagar Colony,
Chennai - 600 015, Tamil Nadu, India

Cost Auditors

Shri J Karthikeyan

Cost Accountant
No.16, Muthalamman Kovil Street
Selaiyur, Chennai - 600 086
Tamil Nadu, India

Secretarial Auditors

S Dhanapal & Associates

Practicing Company Secretaries
Suite No. 103, First Floor, Kaveri Complex,
No. 96/104, Nungambakkam High Road
Nungambakkam, Chennai - 600 034,
Tamil Nadu, India

Internal Auditor

M/s. Singhi & Co.

Chartered Accountants
Unit-11-D, 11th Floor, Ega Trade Centre,
809, Poonamallee High Road, Kilpauk,
Chennai - 600 010, India

Registrar and Share Transfer Agents (w.e.f. 30.07.2021)

Abhipra Capital Limited

A-387, Dilkhush Industrial Area,
G T Karnal Road, Azadpur
Delhi - 110033

Banks / Financial Institutions

Union Bank of India
HDFC Bank Limited

Board of Directors



Shri Ram Gopal Agarwal
Chairman &
Non-Executive Director



Shri Manish Dhanuka
Managing Director



Shri Arun Kumar Dhanuka
Non-Executive Director



Shri Mridul Dhanuka
Whole-time Director



Dr Dharam Vir
Independent Director



Shri Manoj Kumar Goyal
Independent Director



Smt Tanu Singla
Independent Director



Shri Mudit Tandon
Independent Director



DELIVERING EXCELLENCE

is a practice we have built in Orchid through sustained strategic evolution. A global vision and strategy, passion for science and technology and an emphasis on execution and delivery have helped us achieve excellence in our growth journey. Our integrated business model enables us to cater to business opportunities throughout the pharmaceutical value chain, from research to delivery of drugs across all geographies. Our prudent choice of therapeutic areas combined with state-of-the art infrastructure makes us a preferred partner for the development and manufacture of pharmaceutical products. Our niche product basket helps us maintain an edge over our peers in the markets where we are present. Our strategic alliances ensure a wide market reach, enabling us to deliver not only quality products but also achieve better margins. Our strategy seeks to build a sustainable organizational eco-system where one is constantly motivated to attain new heights, empowered to discover new avenues and focused on delivering those commitments.

Contents

06 Message from the Managing Director	13 Financial Highlights	14 Board's Report	24 Management Discussion & Analysis
29 Annexure to the Board's Report (I-III)	33 Report on Corporate Governance	59 Annexure to the Board's Report (V-X)	78 Standalone Auditor's Report
89 Standalone Balance Sheet	91 Statement of P&L, Cash Flow & Change of Equity	96 Notes to Financial Statements	142 Consolidated Auditor's Report
149 Consolidated Balance Sheet	151 Statement of P&L, Cash Flow & Change of Equity	156 Notes to Consolidated Financial Statements	206 Notice of the 29 th Annual General Meeting



Message from the Managing Director

Dear Shareholders

I am delighted to share with you, my message, through this annual report, summarizing Orchid's performance after the acquisition of your Company by Dhanuka Laboratories Limited in March 2020.

When I was inducted as the Managing Director of your company on June 29, 2020, my immediate priority was to strengthen the organizational core capabilities, bring greater stability and continuity to the business and enhance employee morale since your Company was under the Corporate Insolvency Resolution Process for more than two years. The company's core values and open culture led me to feel entirely at home immediately on joining, despite the turbulent time on the business front. For this, I would like to express my gratitude to all the former and current employees who have contributed to building the Orchid culture.

In the past couple of years, every one of us had witnessed tumultuous times with the widespread of COVID-19 pandemic including the disruptive impact caused on the Pharma Sector. Due to the imposition of lockdowns and restricted movements thereof, your company was also exposed to unprecedented challenges, however your Company had strived to ensure that the production at the manufacturing facilities and the supply chains continued undisrupted. Multiple initiatives were implemented for the safety of our employees, including adherence to the COVID safety protocols at the manufacturing facilities and other locations.

It has been two years since the company is functioning under the flagship of the Dhanuka Group and has been embracing the effective Organizational change resulting in enhanced performance and business growth. Your Company has undergone significant transformation and with the unstinted support and contribution of every Orchidian, the company has accomplished significant milestones during the last couple of years.

Post completion of the Corporate Insolvency Resolution Process, your company has crossed the revival phase and evidenced various positive developments. During the year, your Company had implemented significant steps to streamline and simplify the functioning and bring in greater efficiencies. Every passing quarter our performance improved driven by our focus on sustainable growth. During the fiscal, your Company had witnessed reduction of debts, positive trends in sales and operating profits and maintained efficient plant operations. I am elated to share that your Company has achieved an increase in Standalone revenues by 24% for the fiscal ended March 2022. We improved operational performance and margins by maximizing revenues and delivering on our cost optimization efforts. In the future, your company would also continue to evaluate organic and inorganic growth opportunities.

This year your Company would be marking its 30th Anniversary and as an organization, our constant endeavor would be to strengthen our core and transform into a future ready organization.

We have in place a detailed strategic plan to achieve significant growth in short, medium and long term. The key growth drivers would include scaling up of the existing products and launch of new products and penetrating into newer markets in both API and Formulations business. We also strive to accomplish a strong balance sheet with industry leading best practices.

I would like to thank our Board of Directors for their relentless pursuit of excellence throughout the last financial year.

We are grateful to the Central and State Governments and the Central DCGI and State FDAs for their support to the Company's business plans. Your Board places on record their appreciation of the support provided by the customers, suppliers, services providers, medical fraternity and business partners.

We are thankful to the esteemed shareholders for their support and encouragement. The Directors and the Management acknowledge and are thankful to the employees for their commitment and contributions for the revival of the businesses and operations.

Manish Dhanuka
Managing Director



Awards and Accolades

Dr R J Sarangdhar, Vice-President-Unit Head API & FDF received the Export Excellence award for the Financial year 2016-2017 under the "Category Exports above Rs.50 Crore" from Shri. R. N. Ravi - Hon'ble Governor of Tamilnadu - on behalf of Orchid Pharma Ltd., Alathur



Dr R J Sarangdhar, Vice-President-Unit Head API & FDF received the Export Excellence award for the Financial year 2017-2018 under the "Category Exports above Rs.50 Crore" from Shri. R. N. Ravi - Hon'ble Governor of Tamilnadu - on behalf of Orchid Pharma Ltd., Alathur

Dr R J Sarangdhar, Vice-President-Unit Head API & FDF received the Export Excellence award for the Financial year 2018-2019 under the "Category Exports between Rs.10 Crore to 50 Crore" from Smt. Malini Shankar - IAS, Vice Chancellor of Indian Maritime University - on behalf of Orchid Healthcare, Irungattukottai

